Société Générale : The stock needs a breather
Published on 06/16/2021
at 09:18 am BST
| Entry price | Target | Stop-loss | Potential |
|---|
|
€25.92 |
€23.66 |
€26.72 |
+8.72% |
|---|
Société Générale shares have recently benefitted from renewed interest and are reverting to attractive levels at which sales could be contemplated.
SummaryStrengths● Its low valuation, with P/E ratio at 8.57 and 7.8 for the ongoing fiscal year and 2022 respectively, makes the stock pretty attractive with regard to earnings multiples.
●
● This company will be of major interest to investors in search of a high dividend stock.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
●
●
● Historically, the company has been releasing figures that are above expectations.
● According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
●
© MarketScreener.com -
2021
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener UK. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
